ROIV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Roivant Sciences Ltd (ROIV) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the company has positive Phase 2 clinical trial results for brepocitinib and favorable analyst ratings, its financial performance is significantly deteriorating, and insider selling is high. Additionally, the stock's technical indicators and options data do not strongly support a buy decision. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this investment is recommended.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive at 0.521, indicating a bullish trend. However, the RSI_6 at 72.925 is approaching overbought territory. Key resistance levels are at R1: 27.056 and R2: 28.698, while support levels are at S1: 21.738 and S2: 20.096. Overall, the technical indicators suggest a cautiously bullish trend but not a strong buy signal.
Positive Phase 2 trial results for brepocitinib in cutaneous sarcoidosis, with a 100% response rate in the BEACON study.
Analysts have raised price targets significantly, with Citi and H.C. Wainwright setting targets at $35 and $33, respectively.
The stock has bullish moving averages and a positive MACD histogram.
Insider selling has increased by 104.95% over the last month, indicating a lack of confidence from insiders.
Financial performance is severely deteriorating, with revenue down -77.83% YoY and net income down -256.98% YoY in Q3
The stock's historical performance suggests a -4.09% decline in the next month based on similar candlestick patterns.
In Q3 2026, Roivant Sciences reported a significant decline in financial metrics: revenue dropped -77.83% YoY to $1.999 million, net income fell -256.98% YoY to -$265.891 million, and EPS declined -265.22% YoY to -$0.38. Gross margin also dropped to 64.98%, down -33.10% YoY. These figures indicate poor financial health and growth trends.
Analysts are generally bullish on the stock, with multiple firms raising price targets recently due to positive Phase 2 trial results. Targets range from $26 (BofA) to $38 (TD Cowen), with most firms maintaining Buy ratings. However, BofA remains Neutral, citing in-line Q3 results and a cautious outlook.
